News | December 04, 2013

Ziyad Hijazi Appointed Clinical Chief for Pediatrics at Sidra Medical and Research Center in Qatar

December 4, 2013 — Sidra Medical and Research Center, a specialty women's and children's hospital in Qatar, announced that Ziyad Hijazi, M.D., has been appointed clinical chief for pediatrics. In this role, the pioneering clinician will drive the strategic direction of the Department of Pediatrics and integrate research and education priorities into a program of excellent clinical service delivery. He will also hold the position of chair of pediatrics at Weill Cornell Medical College — Qatar, Sidra's partner for medical education.
 
"Sidra will be a beacon of excellence for pediatric care in Qatar and the Middle East so this is a key appointment for us," said Edward Ogata, chief medical officer, Sidra. "Dr. Hijazi's wide-ranging clinical and academic expertise in both pediatrics and cardiology, and his passion for research of the highest quality — evident from his exceptional record of publications — perfectly complement our vision for Sidra. I am particularly pleased that he will be here when Sidra hosts the Excellence in Pediatrics Conference 4-7 December, the first time this major conference has been held here in the Middle East."
 
Hijazi attended the Yale University School of Medicine, where he completed a Master of Public Health degree, a residency in Pediatrics and a fellowship in Pediatric Cardiology. He spent eight years on the faculty at Tufts University School of Medicine and another eight years at the University of Chicago. In 2007, he was appointed professor, Pediatrics and Internal Medicine, director, Rush Center for Congenital and Structural Heart Disease, and section chief, Pediatric Cardiology at Rush University Medical Center.
 
Hijazi specializes in treating congenital and structural heart disease in both children and adults. He is a pioneer in and considered one of the top experts in transcatheter repair of congenital and structural heart defects and a past president of the Society for Cardiovascular Angiography and Interventions (SCAI). 
 
"It's an honor to join Sidra and its prestigious leadership team,” said Hijazi. “I'm optimistic that my work with transcatheter septal defect closure in children, which will be the focus of my presentation at EiP, is helping find alternatives to the invasive open heart surgery which is especially traumatic for pediatric patients and I look forward to bringing these techniques to Sidra."
 
For more information: sidra.org

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init